Berberine-phospholipid nanoaggregate-embedded thiolated chitosan hydrogel for aphthous stomatitis treatment
Aim: This study aimed to develop nanoaggregates of berberine-phospholipid complex incorporated into thiolated chitosan (TCS) hydrogel for the treatment of aphthous stomatitis. Methods: The berberine-phospholipid complex was formulated through the solvent evaporation technique and assembled into nanoaggregates. TCS was synthesized through the attachment of thioglycolic acid to chitosan (CS). Nanoaggregates-TCS was prepared by the incorporation of nanoaggregates into TCS and underwent in vitro and in vivo tests. Results: Nanoaggregates-TCS exhibited prolonged release of berberine. The mucoadhesive strength of nanoaggregates-TCS increased 1.75-fold compared with CS hydrogel. In vivo studies revealed the superior therapeutic efficacy of nanoaggregates-TCS compared with that of other groups. Conclusion: Due to prolonged drug release, appropriate residence time and anti-inflammatory effects, nanoaggregates-TCS is an effective system for the treatment of aphthous stomatitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 18(2023), 19 vom: 15. Aug., Seite 1227-1246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hashtrodylar, Yasaman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aphthous stomatitis |
|---|
| Anmerkungen: |
Date Revised 05.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2217/nnm-2023-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362097135 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362097135 | ||
| 003 | DE-627 | ||
| 005 | 20231226090524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1206.xml |
| 035 | |a (DE-627)NLM362097135 | ||
| 035 | |a (NLM)37712555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hashtrodylar, Yasaman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Berberine-phospholipid nanoaggregate-embedded thiolated chitosan hydrogel for aphthous stomatitis treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Aim: This study aimed to develop nanoaggregates of berberine-phospholipid complex incorporated into thiolated chitosan (TCS) hydrogel for the treatment of aphthous stomatitis. Methods: The berberine-phospholipid complex was formulated through the solvent evaporation technique and assembled into nanoaggregates. TCS was synthesized through the attachment of thioglycolic acid to chitosan (CS). Nanoaggregates-TCS was prepared by the incorporation of nanoaggregates into TCS and underwent in vitro and in vivo tests. Results: Nanoaggregates-TCS exhibited prolonged release of berberine. The mucoadhesive strength of nanoaggregates-TCS increased 1.75-fold compared with CS hydrogel. In vivo studies revealed the superior therapeutic efficacy of nanoaggregates-TCS compared with that of other groups. Conclusion: Due to prolonged drug release, appropriate residence time and anti-inflammatory effects, nanoaggregates-TCS is an effective system for the treatment of aphthous stomatitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a aphthous stomatitis | |
| 650 | 4 | |a berberine | |
| 650 | 4 | |a hydrogel | |
| 650 | 4 | |a nanoaggregates | |
| 650 | 4 | |a phospholipid complex | |
| 650 | 4 | |a prolonged drug delivery | |
| 650 | 4 | |a thiolated chitosan | |
| 700 | 1 | |a Rabbani, Shahram |e verfasserin |4 aut | |
| 700 | 1 | |a Dadashzadeh, Simin |e verfasserin |4 aut | |
| 700 | 1 | |a Haeri, Azadeh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 18(2023), 19 vom: 15. Aug., Seite 1227-1246 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:19 |g day:15 |g month:08 |g pages:1227-1246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 19 |b 15 |c 08 |h 1227-1246 | ||